var data={"title":"Phentermine and topiramate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phentermine and topiramate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/515350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phentermine-and-topiramate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phentermine and topiramate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057041\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Qsymia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14634241\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anorexiant;</li>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        Sympathomimetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059968\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Weight management:</b> Oral: Initial: Phentermine 3.75 mg/topiramate 23 mg once daily for 14 days. Increase dose to phentermine 7.5 mg/topiramate 46 mg once daily for 12 weeks then evaluate weight loss. If 3% of baseline body weight has not been lost, discontinue use or increase dose to phentermine 11.25 mg/topiramate 69 mg once daily for 14 days, and then to phentermine 15 mg/topiramate 92 mg once daily. Evaluate weight loss after 12 weeks on phentermine 15 mg/topiramate 92 mg; if 5% of baseline body weight has not been lost at dose of phentermine 15 mg/topiramate 92 mg gradually discontinue therapy (eg, 1 dose every other day for at least 1 week).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Weight management in type 2 diabetes mellitus (off-label use): </b>Oral: Phentermine 7.5 mg/topiramate 46 mg or phentermine 15 mg/topiramate 92 mg once daily (Garvey 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059969\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059970\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute: Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Avoid use (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate dosing (Garvey 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 49 mL/minute: Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059971\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh class B): Maximum dose: Phentermine 7.5 mg/topiramate 46 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Avoid use (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15893978\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, extended release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qsymia: 3.75/23: Phentermine 3.75 mg [immediate release] and topiramate 23 mg [extended release] [contains tartrazine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qsymia: 7.5/46: Phentermine 7.5 mg [immediate release] and topiramate 46 mg [extended release] [contains tartrazine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qsymia: 11.25/69: Phentermine 11.25 mg [immediate release] and topiramate 69 mg [extended release] [contains tartrazine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qsymia: 15/92: Phentermine 15 mg [immediate release] and topiramate 92 mg [extended release] [contains tartrazine]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15070498\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14634227\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM312590.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WL6F63SkXseA6lKw9ehnBiw==&amp;TOPIC_ID=85870\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM312590.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059973\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer in the morning without regard to meals; avoid late evening administration (potential for insomnia). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14634231\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Weight management:</b> Adjunct to a reduced-calorie diet and increased physical activity, in patients with either an initial body mass index (BMI) of &ge;30 kg/m<sup>2</sup> <b>or</b> an initial BMI of &ge;27 kg/m<sup>2</sup> and at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50408847\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Weight management in type 2 diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057051\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with combination product (also see individual agents):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased heart rate (&gt;5 bpm: 70% to 78%; &gt;10 bpm: 50% to 56%; &gt;15 bpm: 33% to 37%; &gt;20 bpm: 14% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (4% to 20%), headache (10% to 11%), insomnia (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum bicarbonate (6% to 13%; marked reductions [to &lt;17 mEq/L] &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (7% to 19%), constipation (8% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (14% to 16%), nasopharyngitis (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitations (&le;2%), chest discomfort (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3% to 9%), depression (3% to 8%), anxiety (2% to 8%), cognitive dysfunction (including problems with concentration, memory, and language [word finding]; 2% to 8%), fatigue (4% to 6%), hypoesthesia (4%), disturbance in attention (2% to 4%), irritability (2% to 4%), oral paresthesia (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (2% to 4%), skin rash (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum potassium (&lt;3.5 mEq/L: 4% to 5%; &lt;3 mEq/L: &lt;1%), hypokalemia (&le;3%), increased thirst (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (metallic taste; 1% to 9%), nausea (4% to 7%), diarrhea (5% to 6%), gastroesophageal reflux disease (3%), dyspepsia (2% to 3%), gastroenteritis (2% to 3%), decreased appetite (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (5%), dysmenorrhea (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5% to 7%), muscle spasm (3%), musculoskeletal pain (2% to 3%), neck pain (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (4% to 6%), dry eye syndrome (&le;3%), eye pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&ge;0.3 mg/dL: 2% to 8%; &ge;50% over baseline: &le;3%), nephrolithiasis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (7% to 8%), bronchitis (4% to 7%), cough (4% to 5%), pharyngolaryngeal pain (2% to 3%), sinus congestion (2% to 3%), nasal congestion (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Acute angle-closure glaucoma, suicidal ideation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057047\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity or idiosyncrasy to phentermine or other sympathomimetic amines or any component of the formulation; hyperthyroidism; glaucoma; use during or within 14 days following MAO inhibitor therapy; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057048\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Can increase resting heart rate; monitor closely when starting or increasing dosage, and in patients with cardiac or cerebrovascular disease. Reduce dose or discontinue use with a sustained increase in resting heart rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Cognitive dysfunction and psychiatric disturbances (mood disorders including anxiety, depression or insomnia) may occur with use; incidence of cognitive events (including attention or memory difficulties) may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Risk may be increased in patients with a history of depression; dose reduction or discontinuation may be necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Topiramate has been associated with acute myopia and secondary angle-closure glaucoma in adults and children, typically within 1 month of initiation but may occur at any time; discontinue in patients with acute onset of decreased visual acuity or ocular pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthermia: Topiramate may be associated (rarely) with severe oligohidrosis and hyperthermia; use caution and monitor closely during strenuous exercise, during exposure to high environmental temperature, or in patients receiving other carbonic anhydrase inhibitors and drugs with anticholinergic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Can cause hypokalemia; use caution with concurrent use of hydrochlorothiazide or furosemide as risk of hypokalemia may be increased; monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: In hypertensive patients, weight loss in conjunction with antihypertensive therapy may increase the risk of hypotension; monitor blood pressure and adjust antihypertensive treatment as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic acidosis (hyperchloremic, nonanion gap): May decrease serum bicarbonate concentrations, due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Risk may be increased in patients with conditions that predispose to acidosis (eg, diarrhea, ketogenic diet, renal disease, severe respiratory disorders, status epilepticus, surgery) or concurrent treatment with other carbonic anhydrase inhibitors. Monitor serum electrolytes and bicarbonate prior to and during treatment.  Reduce dose or discontinue use if persistent metabolic acidosis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal calculus: Use is associated with kidney stone formation. Topiramate exhibits weak carbonic anhydrase inhibitory properties and may increase the risk of kidney stones.  The risk of stones may be increased in patients on a ketogenic diet or concurrent treatment with other carbonic anhydrase inhibitors; risk of stones may be reduced by increasing fluid intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: May increase serum creatinine; peak increases from baseline were observed after 4-8 weeks of treatment. Monitor serum creatinine prior to and during treatment. For persistent elevations, dose reduction or discontinuation may be necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after  initiation and continued through duration of trials (most trials &le;24 weeks). Avoid use in patients with history of suicide attempts or current suicidal ideation. Monitor all patients for notable changes in behavior and discontinue use in patients who experience suicidal thoughts or new onset or worsening depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with type 2 diabetes mellitus; antidiabetic agent requirements (eg, insulin or oral hypoglycemic agents) may be decreased with weight loss, anorexigens and concomitant dietary restrictions. Monitor blood glucose levels prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required. Avoid use in patients with severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sedatives: Avoid use with other sedative drugs or ethanol; CNS effects may be potentiated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: Phentermine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize the possibility of overdose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants (including topiramate) should not be discontinued abruptly because of the possibility of increasing seizure frequency. Therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Tapering doses over at least 1 week (1 dose every other day) is recommended. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14878056\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14878054\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85870&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR).  Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. Management: Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) is contraindicated.  Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May decrease the excretion of Amphetamines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Topiramate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Topiramate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Topiramate may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypokalemic effect of Topiramate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Topiramate may enhance the adverse/toxic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Topiramate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: Topiramate may decrease the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Topiramate may decrease the serum concentration of Progestins (Contraceptive).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Topiramate may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Topiramate may enhance the adverse/toxic effect of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057042\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057043\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of this combination product is contraindicated in pregnant women. Based on human data, topiramate may cause fetal harm if used during pregnancy. An increased risk of adverse maternal and fetal outcomes is associated with obesity; however, medications for weight loss therapy are not recommended at conception or during pregnancy (ACOG 156 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential should have a negative pregnancy test prior to and monthly during therapy. Effective contraception should be used during treatment. If irregular bleeding or spotting occurs while using hormonal contraceptives during therapy, patients should be instructed to continue the contraceptive (contraceptive failure is not expected) and notify their health care provider if symptoms become troubling. Refer to individual monographs for additional information.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to Qsymia during pregnancy in the Qsymia Pregnancy Surveillance Program (888-998-4887).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15057046\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Topiramate and amphetamines are excreted in breast milk. Due to the potential for adverse effects, the manufacturer recommends to discontinue therapy or discontinue breast-feeding. Refer to individual monographs for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059972\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take in the morning; avoid taking in the late evening. Most effective when combined with a low calorie diet, increased physical activity and behavior modification counseling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059975\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Weight; resting heart rate; serum bicarbonate, potassium, glucose, and serum creatinine (at baseline and periodically during treatment); blood pressure; suicidality or mood disorders; symptoms of secondary angle closure glaucoma; symptoms of acute acidosis and complications of long-term acidosis (eg, nephrolithiasis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059962\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phentermine: A sympathomimetic amine with pharmacologic properties similar to amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Topiramate: Effect on weight management may be due to its effects on appetite suppression and satiety enhancement and based on a combination of potential mechanisms: blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainite glutamate receptors, and weakly inhibits carbonic anhydrase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15059964\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570444\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Qsymia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.75-23 mg (30): $216.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5-46 mg (30): $223.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.25-69 mg (30): $239.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15-92 mg (30): $239.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No 156: Obesity in Pregnancy. <i>Obstet Gynecol</i>. 2015;126(6):e112-3126. doi: 10.1097/AOG.0000000000001211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentermine-and-topiramate-drug-information/abstract-text/26595582/pubmed\" target=\"_blank\" id=\"26595582\">26595582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27219496\"></a>Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients With Obesity. <i>Endocr Pract</i>. 2016;22 Suppl 3:1-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentermine-and-topiramate-drug-information/abstract-text/27219496/pubmed\" target=\"_blank\" id=\"27219496\">27219496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25249652\"></a>Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. <i>Diabetes Care</i>. 2014;37(12):3309-3316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentermine-and-topiramate-drug-information/abstract-text/25249652/pubmed\" target=\"_blank\" id=\"25249652\">25249652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qsymia [prescribing information]. Mountain View, CA: VIVUS Inc; October 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85870 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15057041\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14634241\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15059968\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15059969\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15059970\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15059971\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15893978\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F15070498\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F14634227\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15059973\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14634231\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50408847\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15057051\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15057047\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15057048\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14878056\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14878054\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F15057042\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15057043\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15057046\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F15059972\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15059975\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15059962\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15059964\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570444\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85870|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phentermine-and-topiramate-patient-drug-information\" class=\"drug drug_patient\">Phentermine and topiramate: Patient drug information</a></li></ul></div></div>","javascript":null}